Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders: 2023-2025
Historic Net Income towards Common Stockholders for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$32.0 million.
- Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders fell 125.22% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.2 million, marking a year-over-year increase of 26.64%. This contributed to the annual value of -$130.0 million for FY2024, which is 11.47% down from last year.
- According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders is -$32.0 million, which was down 13.22% from -$28.3 million recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders registered a high of -$14.2 million during Q3 2024, and its lowest value of -$78.8 million during Q2 2024.
- Over the past 3 years, Tonix Pharmaceuticals Holding's median Net Income towards Common Stockholders value was -$27.3 million (recorded in 2023), while the average stood at -$29.2 million.
- Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders showed a top increase of 64.11% in 2025 and a maximum decrease of 125.22% in 2025.
- Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders (Quarterly) stood at -$27.3 million in 2023, then grew by 19.08% to -$22.1 million in 2024, then tumbled by 125.22% to -$32.0 million in 2025.
- Its Net Income towards Common Stockholders was -$32.0 million in Q3 2025, compared to -$28.3 million in Q2 2025 and -$16.8 million in Q1 2025.